InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio Sells 5,398 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $8.87, for a total transaction of $47,880.26. Following the completion of the sale, the chief executive officer now owns 416,659 shares of the company’s stock, valued at approximately $3,695,765.33. This represents a 1.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Richard Dilorio also recently made the following trade(s):

• On Monday, November 25th, Richard Dilorio sold 20,000 shares of InfuSystem stock. The stock was sold at an average price of $9.32, for a total value of $186,400.00.

InfuSystem Price Performance

Shares of INFU stock opened at $8.85 on Thursday. The stock’s fifty day simple moving average is $7.29. InfuSystem Holdings, Inc. has a 1-year low of $5.74 and a 1-year high of $10.99. The stock has a market cap of $188.19 million, a P/E ratio of 147.50 and a beta of 1.45. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Institutional Investors Weigh In On InfuSystem

A number of large investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its position in shares of InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after purchasing an additional 1,626 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after buying an additional 2,145 shares during the period. State Street Corp grew its holdings in shares of InfuSystem by 1.1% during the third quarter. State Street Corp now owns 267,012 shares of the company’s stock valued at $1,789,000 after buying an additional 3,019 shares during the last quarter. ARS Investment Partners LLC increased its position in shares of InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after acquiring an additional 3,422 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in InfuSystem by 6.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after acquiring an additional 5,391 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. B. Riley started coverage on InfuSystem in a research note on Thursday, September 26th. They issued a “buy” rating and a $13.00 target price on the stock. StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.